The board of directors of Eli Lilly (LLY) and Company elected Carolyn Bertozzi, as a returning member, effective Dec. 8, 2025. She will serve on the board’s Science and Technology and Ethics and Compliance committees. Currently serving as the Baker Family director of Sarafan ChEM-H, Anne T. and Robert M. Bass professor in the School of Humanities and Sciences and professor, by courtesy, of Chemical and Systems Biology and of Radiology at Stanford University, Dr. Bertozzi is also an Investigator of the Howard Hughes Medical Institute.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly’s Mounjaro added to China’s health insurance list, Reuters says
- LLY, PFE: Eli Lilly’s Mounjaro, Pfizer’s Cancer Drug Added to China’s State Insurance List
- Eli Lilly announces Phase 3 BRUIN CLL-314 met primary endpoint
- Eli Lilly, Pfizer, Johnson secure spots on China’s drug catalog, Bloomberg says
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’